CEST 2022-three-dimensional amide proton transfer (APT) imaging can identify the changes of cerebral cortex in Parkinson's disease
Magnetic Resonance Imaging · 2023
DOI: 10.1016/j.mri.2023.06.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Magnetic Resonance Imaging, 2023. Verfasst von Yaotian Tian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, 1007…. Hauptthemen laut MEDLINE: Brain Neoplasms, Parkinson Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
PURPOSE: Amide proton transfer (APT) imaging has shown its diagnostic and predictive superiority in Parkinson's disease (PD) in our previous studies using 2D APT imaging based on deep nuclei. We hypothesized that the pathophysiological abnormality of PD will change the APT-related parameters in the cerebral cortex, and the signal changes can contribute to accurate diagnosis of PD. METHODS: 34 patients with idiopathic Parkinson's disease (IPD) and 29 age- and sex-matched normal controls (NC) were enrolled in this prospective study. 3D-APT imaging and 3D-T1WI was performed in our participants. A volume-based morphometry algorithm was used and get automated cortical segmentations. Quantitative parameter maps of APT-related metrics were calculated by using SPM and MATLAB. The unpaired Student's t-test or Mann-Whitney U test was used for comparison of these values between IPD and NC groups. The associations between APT-related metrics and clinical assessments were investigated by Spearman correlation analysis. The receiver-operating characteristic (ROC) analysis was used to assess the diagnostic performances. The binary logistic regression model was used to combine the imaging parameters. RESULTS: There wasn't any correlations between cortical APT-related signals and clinical assessment, including the H&Y scale, the disease duration, the UPDRS III scores and the MMSE scores. The MTRasym, CESTRnr and MTRRex had significantly higher values (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, 100730 Beijing, China; Graduate School of Peking Union Medical College, Ch…
- Department of Neurology, National Center of Gerontology, Beijing Hospital, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, 100730 Beijing, China.
- Key Laboratory for Biomedical Engineering of Ministry of Education, Department of Biomedical Engineering, College of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou 310027, Zhejiang, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Tian, Y., Li, X., Wang, X., Su, W., Li, S., Wang, W., Zhang, Y., Li, C., & Chen, M. (2023). CEST 2022-three-dimensional amide proton transfer (APT) imaging can identify the changes of cerebral cortex in Parkinson's disease. Magnetic Resonance Imaging. https://doi.org/10.1016/j.mri.2023.06.006
Vancouver
Tian Y, Li X, Wang X, Su W, Li S, Wang W, et al. CEST 2022-three-dimensional amide proton transfer (APT) imaging can identify the changes of cerebral cortex in Parkinson's disease. Magnetic Resonance Imaging. 2023. doi:10.1016/j.mri.2023.06.006
BibTeX
@article{Tian2023,
author = {Tian, Yaotian and Li, Xinyang and Wang, Xiaonan and Su, Wen and Li, Shuhua and Wang, Wenqi and Zhang, Yi and Li, Chunmei and Chen, Min},
title = {CEST 2022-three-dimensional amide proton transfer (APT) imaging can identify the changes of cerebral cortex in Parkinson's disease},
journal = {Magnetic Resonance Imaging},
year = {2023},
doi = {10.1016/j.mri.2023.06.006}
}
EUVIMED